Your browser doesn't support javascript.
loading
Treatment of allergic rhinitis using mobile technology with real-world data: The MASK observational pilot study.
Bousquet, J; Devillier, P; Arnavielhe, S; Bedbrook, A; Alexis-Alexandre, G; van Eerd, M; Murray, R; Canonica, G W; Illario, M; Menditto, E; Passalacqua, G; Stellato, C; Triggiani, M; Carreiro-Martins, P; Fonseca, J; Morais Almeida, M; Nogueira-Silva, L; Pereira, A M; Todo Bom, A; Bosse, I; Caimmi, D; Demoly, P; Fontaine, J F; Just, J; Onorato, G L; Kowalski, M L; Kuna, P; Samolinski, B; Anto, J M; Mullol, J; Valero, A; Tomazic, P V; Bergmann, K C; Keil, T; Klimek, L; Mösges, R; Shamai, S; Zuberbier, T; Murphy, E; McDowall, P; Price, D; Ryan, D; Sheikh, A; Chavannes, N H; Fokkens, W J; Kvedariene, V; Valiulis, A; Bachert, C; Hellings, P W; Kull, I.
Afiliação
  • Bousquet J; Contre les MAladies Chroniques Pour un VIeillissement Actif en France, European Innovation Partnership on Active and Healthy Ageing Reference Site, MACVIA-France, Montpellier, France.
  • Devillier P; INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Université Versailles St-Quentin-en-Yvelines, UMR-S168, Villejuif, Montigny le Bretonneux, France.
  • Arnavielhe S; Euforea, Brussels, Belgium.
  • Bedbrook A; Laboratoire de Pharmacologie Respiratoire UPRES EA220, Pôle des Maladies Respiratoires, Hôpital Foch, Suresnes - Université Versailles Saint-Quentin, Versailles, France.
  • Alexis-Alexandre G; Kyomed, Montpellier, France.
  • van Eerd M; Contre les MAladies Chroniques Pour un VIeillissement Actif en France, European Innovation Partnership on Active and Healthy Ageing Reference Site, MACVIA-France, Montpellier, France.
  • Murray R; EZY, Montpellier, France.
  • Canonica GW; Peercode BV, Gerdermalsen, The Netherlands.
  • Illario M; Medical Communications Consultant, MedScript Ltd, Dundalk, Ireland.
  • Menditto E; Allergy and Respiratory Diseases, Department of Internal Medicine, IRCCS San Martino-IST-University of Genoa, Genoa, Italy.
  • Passalacqua G; Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R&D and DISMET), Naples, Italy.
  • Stellato C; Center of Pharmacoeconomics, CIRFF, University of Naples Federico II, Naples, Italy.
  • Triggiani M; Allergy and Respiratory Diseases, Department of Internal Medicine, IRCCS San Martino-IST-University of Genoa, Genoa, Italy.
  • Carreiro-Martins P; Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno, Italy.
  • Fonseca J; Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno, Italy.
  • Morais Almeida M; Servicio de Imunoalergologia, EPE - Nova Medical School, Respiratory Research Group, CEDOC, Centro Hospitalar de Lisboa Central, Lisbon, Portugal.
  • Nogueira-Silva L; Faculdade de Medicina, Center for Health Technology and Services Research-CINTESIS, Universidade do Porto, Porto, Portugal.
  • Pereira AM; Allergy Unit, CUF Porto Instituto & Hospital, Porto, Portugal.
  • Todo Bom A; Rhinology Unit & Smell Clinic, ENT Department, Hospital Clinic, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain.
  • Bosse I; Department of Internal Medicine, Center for Health Technology and Services Research-CINTESIS, Centro Hospitalar Sao Joao, Porto, Portugal.
  • Caimmi D; Allergy Unit, CUF Porto Instituto & Hospital, Porto, Portugal.
  • Demoly P; Immunoallergy Department, CUF-Descobertas Hospital, Lisbon, Portugal.
  • Fontaine JF; Health Information and Decision Sciences Department, Faculty of Medicine of the University of Porto, Porto, Portugal.
  • Just J; Imunoalergologia, Centro Hospitalar Universitario de Coimbra, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
  • Onorato GL; Allergist, La Rochelle, France.
  • Kowalski ML; CHU de Montpellier, UPMC, Paris 06, UMR-S 1136, IPLESP, Equipe EPAR, Sorbonne Universités, Paris, France.
  • Kuna P; CHU de Montpellier, UPMC, Paris 06, UMR-S 1136, IPLESP, Equipe EPAR, Sorbonne Universités, Paris, France.
  • Samolinski B; Allergist, Reims, France.
  • Anto JM; Allergology Department, Centre de l'Asthme et des Allergies, Hôpital d'Enfants Armand-Trousseau - INSERM, UMRS 1136, UPMC Univ Paris 06 - Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe EPAR, Sorbonne Universités, Paris, France.
  • Mullol J; Contre les MAladies Chroniques Pour un VIeillissement Actif en France, European Innovation Partnership on Active and Healthy Ageing Reference Site, MACVIA-France, Montpellier, France.
  • Valero A; Department of Immunology, Rheumatology and Allergy, Medical University of Lodz, Lodz, Poland.
  • Tomazic PV; HARC, Lodz, Poland.
  • Bergmann KC; Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.
  • Keil T; Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland.
  • Klimek L; ISGLoBAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain.
  • Mösges R; IMIM (Hospital del Mar Research Institute), Barcelona, Spain.
  • Shamai S; CIBER Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.
  • Zuberbier T; Universitat Pompeu Fabra (UPF), Barcelona, Spain.
  • Murphy E; Rhinology Unit & Smell Clinic, ENT Department, Hospital Clinic, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain.
  • McDowall P; Pneumology and Allergy Department Hospital Clinic, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain.
  • Price D; Department of ENT, Medical University of Graz, Graz, Austria.
  • Ryan D; Comprehensive Allergy-Centre-Charité, Department of Dermatology and Allergy, Global Allergy and Asthma European Network (GA2LEN), Charité Universitatsmedizin Berlin, Berlin, Germany.
  • Sheikh A; Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitatsmedizin, Berlin, Germany.
  • Chavannes NH; Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Wuerzburg, Germany.
  • Fokkens WJ; Center for Rhinology and Allergology, Wiesbaden, Germany.
  • Kvedariene V; Institute of Medical Statistics and Computational Biology, Medical Faculty, University of Cologne, Cologne, Germany.
  • Valiulis A; CRI-Clinical Research International-Ltd, Hamburg, Germany.
  • Bachert C; Institute of Medical Statistics and Computational Biology, Medical Faculty, University of Cologne, Cologne, Germany.
  • Hellings PW; CRI-Clinical Research International-Ltd, Hamburg, Germany.
  • Kull I; Comprehensive Allergy-Centre-Charité, Department of Dermatology and Allergy, Global Allergy and Asthma European Network (GA2LEN), Charité Universitatsmedizin Berlin, Berlin, Germany.
Allergy ; 73(9): 1763-1774, 2018 09.
Article em En | MEDLINE | ID: mdl-29336067
ABSTRACT

BACKGROUND:

Large observational implementation studies are needed to triangulate the findings from randomized control trials as they reflect "real-world" everyday practice. In a pilot study, we attempted to provide additional and complementary insights on the real-life treatment of allergic rhinitis (AR) using mobile technology.

METHODS:

A mobile phone app (Allergy Diary, freely available in Google Play and Apple App stores) collects the data of daily visual analog scales (VAS) for (i) overall allergic symptoms, (ii) nasal, ocular, and asthma symptoms, (iii) work, as well as (iv) medication use using a treatment scroll list including all medications (prescribed and over the counter (OTC)) for rhinitis customized for 15 countries.

RESULTS:

A total of 2871 users filled in 17 091 days of VAS in 2015 and 2016. Medications were reported for 9634 days. The assessment of days appeared to be more informative than the course of the treatment as, in real life, patients do not necessarily use treatment on a daily basis; rather, they appear to increase treatment use with the loss of symptom control. The Allergy Diary allowed differentiation between treatments within or between classes (intranasal corticosteroid use containing medications and oral H1-antihistamines). The control of days differed between no [best control], single, or multiple treatments (worst control).

CONCLUSIONS:

This study confirms the usefulness of the Allergy Diary in accessing and assessing everyday use and practice in AR. This pilot observational study uses a very simple assessment (VAS) on a mobile phone, shows novel findings, and generates new hypotheses.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Aplicativos Móveis / Rinite Alérgica Tipo de estudo: Clinical_trials / Observational_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Allergy Ano de publicação: 2018 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Aplicativos Móveis / Rinite Alérgica Tipo de estudo: Clinical_trials / Observational_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Allergy Ano de publicação: 2018 Tipo de documento: Article País de afiliação: França